April Tate
Primary Care · Dothan, ALNPI 1801446190
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,750 of the $16,016 with a category attached, or 67.1%. Amgen accounts for 78.3% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2023 at $7,896 and has fallen 81.4% since, to $1,467 in 2025. Among primary care clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 226 payments — averaging $70.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$13K
- Novo Nordisk$1K
- Lilly USA, LLC$682
- AstraZeneca$495
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$174
- Biohaven Pharmaceuticals, Inc.$115
- plus $885 from 19 others
What the payments were for
- Speaking & faculty fees$10,75067%
- Travel & lodging$7805%
- Food & beverage$4,47428%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 61 | $12,543 |
| Novo Nordisk | 41 | $1,121 |
| Lilly USA, LLC | 39 | $682 |
| AstraZeneca | 26 | $495 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $174 |
| Biohaven Pharmaceuticals, Inc. | 1 | $115 |
| GSK | 6 | $105 |
| Kowa Pharmaceuticals America, Inc. | 5 | $98 |
| Boehringer Ingelheim | 4 | $72 |
| EMD Serono, Inc. | 3 | $71 |
| Merck | 3 | $61 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Phathom Pharmaceuticals, Inc. | 4 | $54 |
| AbbVie | 3 | $52 |
| Novartis | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Pfizer | 2 | $41 |
| Abbott | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Smith+Nephew | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Eisai Inc. | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$11,899
- RYBELSUS$250
- Wegovy$125
- NURTEC ODT$115
- ZEPBOUND$111
How this compares
$16,016 in reported general payments places this provider in the 95th percentile of 159 primary care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 181 | $207,120 |
| JanuviaSitagliptin Phosphate | 87 | $127,607 |
| MounjaroTirzepatide | 107 | $123,760 |
| Repatha SureclickEvolocumab | 126 | $96,269 |
| JardianceEmpagliflozin | 84 | $92,479 |
| FarxigaDapagliflozin Propanediol | 97 | $81,293 |
| EliquisApixaban | 92 | $60,104 |
| GlyxambiEmpagliflozin/Linagliptin | 64 | $57,531 |
| RybelsusSemaglutide | 42 | $51,387 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $48,278 |
| VascepaIcosapent Ethyl | 70 | $33,016 |
| LinzessLinaclotide | 26 | $25,016 |
| MyrbetriqMirabegron | 23 | $20,470 |
| TrulicityDulaglutide | 23 | $18,432 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $18,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,121 | $258,507223 claims |
| Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr, Tradjenta | $72 | $185,704178 claims |
| MerckJanuvia, Janumet, Belsomra, Steglatro | $61 | $150,569132 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $682 | $144,129143 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $495 | $129,571160 claims |
| PfizerEliquis | $41 | $60,10492 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $105 | $27,67941 claims |
| AbbVieLinzess | $52 | $25,01626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 159 primary care providers in Alabama.
Other primary care in Dothan
- Keith MatthewsOpelika$20K
- Troy HendersonFultondale$18K
- Brandy McGrawMobile$14K
- Cleo ValdezHuntsville$14K
- Larissa RobinsonJasper$11K
- Jamie GhrigsbyMoulton$9K
- Josh WarrenBirmingham$9K
- Amber NelsonHoover$9K
- Valerie ZiemanFoley$8K
- Tammy CorneliusCullman$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.